| Literature DB >> 26264130 |
Carlos K H Wong1, William C W Wong2, Eric Y F Wan2, Winnie H T Wong2, Frank W K Chan3, Cindy L K Lam2.
Abstract
AIMS: To assess the effect of a structured education intervention, Patient Empowerment Programme (PEP) patient-reported health-related quality of life (HRQOL) among type 2 diabetes mellitus (T2DM) patients, and if positive effect is confirmed, to further explore any association between frequency of sessions attendance and HRQOL.Entities:
Mesh:
Year: 2015 PMID: 26264130 PMCID: PMC4533960 DOI: 10.1186/s12955-015-0324-3
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Baseline Characteristics of Respondents and Non-respondents in PEP Participants
| Total | Respondents | Non-respondents | |||
|---|---|---|---|---|---|
| Characteristic | (N = 298) | (N = 257) | (N = 41) | P-value* | |
| Socio-demographic | |||||
| Age (year, Mean ± SD) | 62.0 ± 9.6 | 61.7 ± 9.6 | 63.6 ± 9.6 | 0.250 | |
| Sex (n, %) | 0.204 | ||||
| Male | 147 (49.3 %) | 123 (47.9 %) | 24 (58.5 %) | ||
| Female | 151 (50.7 %) | 134 (52.1 %) | 17 (41.5 %) | ||
| Smoking status (n, %) | 0.535 | ||||
| Non-smoker | 223 (76.1 %) | 191 (75.5 %) | 32 (80.0 %) | ||
| Ever smoking | 70 (23.9 %) | 62 (24.5 %) | 8 (20.0 %) | ||
| Alcohol status (n, %) | 0.821 | ||||
| non-drinker | 208 (71.0 %) | 179 (70.8 %) | 29 (72.5 %) | ||
| Ever drinking | 85 (29.0 %) | 74 (29.2 %) | 11 (27.5 %) | ||
| Educational level (n, %) | 0.051 | ||||
| Secondary or below | 17 (5.8 %) | 12 (4.7 %) | 5 (12.5 %) | ||
| Tertiary or above | 276 (94.2 %) | 241 (95.3 %) | 35 (87.5 %) | ||
| Clinical | |||||
| Biometric Data (Mean ± SD) | |||||
| Weight (kg) | 65.3 ± 12.1 | 65.5 ± 12.4 | 63.6 ± 10.3 | 0.363 | |
| BMI (kg/m2) | 25.7 ± 3.7 | 25.7 ± 3.7 | 25.1 ± 3.6 | 0.332 | |
| Waist (cm) | 90.4 ± 9.7 | 90.6 ± 9.8 | 88.8 ± 9.7 | 0.297 | |
| HbA1c (%) | 7.2 ± 1.2 | 7.3 ± 1.2 | 7.1 ± 0.9 | 0.495 | |
| SBP (mmHg) | 135.9 ± 17.0 | 136.2 ± 17.4 | 134.1 ± 14.2 | 0.456 | |
| DBP (mmHg) | 77.2 ± 11.2 | 77.2 ± 11.6 | 76.8 ± 8.9 | 0.830 | |
| LDL-C (mmol/L) | 2.8 ± 0.8 | 2.9 ± 0.8 | 2.8 ± 0.8 | 0.806 | |
| TC (mmol/L) | 4.7 ± 0.9 | 4.7 ± 0.9 | 4.8 ± 1.1 | 0.747 | |
| HDL-C (mmol/L) | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.3 ± 0.4 | 0.873 | |
| TG (mmol/L) | 1.5 ± 0.9 | 1.5 ± 0.9 | 1.8 ± 1.0 | 0.091 | |
| Duration of DM (year, Mean ± SD) | 7.3 ± 5.9 | 7.3 ± 6.0 | 7.3 ± 5.5 | 0.981 | |
| Diabetic complication (n, %) | 11 (3.7 %) | 10 (3.9 %) | 1 (2.4 %) | 0.647 | |
| Hypertension (n, %) | 238 (79.9 %) | 207 (80.5 %) | 31 (75.6 %) | 0.464 | |
| Treatment Modality (n, %) | 0.884 | ||||
| Diet only | 31 (10.4 %) | 27 (10.5 %) | 4 (9.8 %) | ||
| Oral and/or insulin treated | 267 (89.6 %) | 230 (89.5 %) | 37 (90.2 %) | ||
Note:
HbA1c Haemoglobin A1c, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, LDL-C Low Density Lipoprotein – Cholesterol, BMI Body Mass Index, TC Total Cholesterol, TG Triglycerides
*Statistically different (P < 0.05) between PEP and non-PEP groups by independent t-test or Chi-square test, where appropriate
Descriptive Statistics of Health-related Quality of Life, and their Changes from PEP Enrollment at baseline to 12-month follow-up
| PEP Enrollment at Baseline | 12-month After Baseline | Change over Time (n = 179) | ||||
|---|---|---|---|---|---|---|
| HRQOL | Mean | 95%CI | P-value* | |||
| SF-12v2 | ||||||
| PF | 87.3 ± 22.9 | 88.3 ± 20.1 | 1.2 ± 21.5 | (−1.9, 4.4) | 0.440 | |
| RP | 89.5 ± 20.1 | 89.5 ± 20.5 | −0.1 ± 20.7 | (−3.1, 3.0) | 0.964 | |
| BP | 81.4 ± 28.7 | 86.0 ± 23.9 | 6.0 ± 28.5 | (1.9, 10.2) | 0.005 | |
| GH | 40.7 ± 25.0 | 36.5 ± 23.7 | −3.6 ± 29.2 | (−7.9, 0.6) | 0.095 | |
| VT | 71.3 ± 26.5 | 74.0 ± 17.5 | 3.7 ± 25.5 | (0.0, 7.4) | 0.052 | |
| SF | 91.3 ± 21.2 | 92.3 ± 19.3 | 1.0 ± 22.1 | (−2.3, 4.2) | 0.560 | |
| RE | 88.5 ± 19.1 | 90.8 ± 16.3 | 2.7 ± 16.9 | (0.2, 5.1) | 0.034 | |
| MH | 79.9 ± 18.1 | 81.0 ± 15.9 | 0.5 ± 17.2 | (−2.1, 3.0) | 0.706 | |
| PCS | 49.1 ± 8.9 | 49.0 ± 7.7 | 0.4 ± 8.5 | (−0.9, 1.6) | 0.548 | |
| MCS | 56.4 ± 9.5 | 57.2 ± 7.4 | 0.8 ± 8.7 | (−0.5, 2.1) | 0.229 | |
| SF-6D | 0.847 ± 0.148 | 0.869 ± 0.135 | 0.026 ± 0.124 | (0.008, 0.044) | 0.006 | |
Note:
PEP = Patient Empowerment Programme; HRQOL = Health-related Quality of Life; PF = Physical Functioning; RP = Role Physical; BP = Bodily Pain; GH = General Health; VT = Vitality; SF = Social Functioning; RE = Role Emotional; MH = Mental Health; PCS = Physical Composite Summary; MCS = Mental Composite Summary
*P-value of testing significance in mean changes using paired t-test
Health-related Quality of Life according to the number of PEP session attendance
| PEP session attendance | |||||||
|---|---|---|---|---|---|---|---|
| HRQOL | 1 (n = 25) | 2 (n = 49) | 3-6 (n = 41) | ≥7 (n = 64) | P-value* | ||
| Change in SF-12v2 | |||||||
| PF | −3.8 ± 16.9 | 3.5 ± 21.4 | 2.3 ± 21.0 | 0.8 ± 23.6 | 0.546 | ||
| RP | −7.2 ± 23.2 | 1.3 ± 15.0 | −2.3 ± 17.9 | 3.3 ± 24.4 | 0.137 | ||
| BP | 8.7 ± 33.1 | 13.5 ± 27.8 | −1.2 ± 22.7 | 3.9 ± 29.6 | 0.081 | ||
| GH | −11.7 ± 25.3 | 0.1 ± 24.8 | −5.6 ± 33.8 | −2.0 ± 30.4 | 0.360 | ||
| VT | 1.9 ± 27.3 | 4.0 ± 23.9 | 1.8 ± 27.3 | 5.5 ± 25.4 | 0.881 | ||
| SF | −3.8 ± 32.9 | 0.0 ± 12.4 | −1.7 ± 18.4 | 5.5 ± 24.6 | 0.203 | ||
| RE | −1.0 ± 16.6 | 5.5 ± 14.3 | −2.0 ± 15.9 | 5.1 ± 18.9 | 0.063 | ||
| MH | −4.0 ± 23.0 | 3.3 ± 14.4 | −1.5 ± 14.1 | 1.4 ± 18.4 | 0.294 | ||
| PCS | −1.5 ± 9.2 | 1.9 ± 7.7 | −0.4 ± 7.0 | 0.4 ± 9.5 | 0.374 | ||
| MCS | −0.8 ± 10.8 | 1.3 ± 6.9 | −0.9 ± 7.7 | 2.1 ± 9.6 | 0.249 | ||
| Change in SF-6D | 0.000 ± 0.139 | 0.064 ± 0.106 | 0.001 ± 0.110 | 0.024 ± 0.134 | 0.059 | ||
| Generic session attendance | DM-specific session attendance | P-value** | |||||
| Non-attendees | Attendees | Non-attendees | Attendees | DM-specific | |||
| HRQOL | 0 (n = 23) | ≥1 (n = 156) | 0 (n = 29) | ≥1 (n = 150) | Generic | ||
| Change in SF-12v2 | |||||||
| PF | 4.3 ± 19.4 | 0.8 ± 21.8 | −5.0 ± 15.3 | 2.5 ± 22.4 | 0.458 | 0.083 | |
| RP | 3.3 ± 10.1 | −0.5 ± 21.8 | −9.6 ± 24.5 | 1.8 ± 19.4 | 0.411 | 0.006 | |
| BP | 19.6 ± 31.9 | 4.1 ± 27.5 | 5.0 ± 26.6 | 6.3 ± 29.0 | 0.015 | 0.827 | |
| GH | 0.4 ± 17.5 | −4.2 ± 30.5 | −7.7 ± 27.2 | −2.8 ± 29.5 | 0.476 | 0.408 | |
| VT | 3.3 ± 23.0 | 3.8 ± 26.0 | −1.7 ± 26.2 | 4.8 ± 25.4 | 0.929 | 0.208 | |
| SF | −4.3 ± 9.7 | 1.7 ± 23.3 | −3.3 ± 31.3 | 1.8 ± 19.9 | 0.220 | 0.247 | |
| RE | 2.7 ± 10.6 | 2.7 ± 17.6 | −2.1 ± 19.7 | 3.6 ± 16.2 | 0.987 | 0.093 | |
| MH | 2.7 ± 17.7 | 0.2 ± 17.2 | 1.3 ± 22.2 | 0.3 ± 16.2 | 0.508 | 0.784 | |
| PCS | 3.3 ± 7.3 | −0.1 ± 8.6 | −2.7 ± 7.3 | 1.0 ± 8.6 | 0.073 | 0.032 | |
| MCS | −0.3 ± 8.5 | 0.9 ± 8.8 | 0.4 ± 9.8 | 0.9 ± 8.5 | 0.517 | 0.781 | |
| Change in SF-6D | 0.086 ± 0.109 | 0.017 ± 0.124 | −0.011 ± 0.138 | 0.033 ± 0.120 | 0.012 | 0.077 | |
Note:
PEP Patient Empowerment Programme, HRQOL Health-related Quality of Life, PF Physical Functioning, RP Role Physical, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role Emotional, MH Mental Health, PCS Physical Composite Summary, MCS Mental Composite Summary
*P-value of testing significance using one-way ANOVA
**P-value of testing significance between non-attendees and attendees using paired t-test